Skip to main content

Table 5 Adverse events that could be related to the treatment

From: A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain

Adverse eventNumber of episodesCategories of the adverse eventsNumber of patients affected
Vaginal bleeding23Reproduction13
Depression2Psychiatric disorders2
Loss of libido2Psychiatric disorders2
Mood swings1Psychiatric disorders1
Hot flush10Vascular9
Night sweats2Skin disorders2
Pain at injection site2General Disorders1